嘉事堂(002462) - 2022 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2022 was ¥12,706,434,721.05, representing a 1.15% increase compared to ¥12,561,786,991.15 in the same period last year[20]. - The net profit attributable to shareholders decreased by 3.24% to ¥169,486,663.20 from ¥175,169,586.50 year-on-year[20]. - Basic earnings per share decreased by 3.33% to ¥0.58 from ¥0.60 in the same period last year[20]. - The company reported a total profit for the first half of 2022 of ¥342,968,680.24, down 20.29% from ¥430,764,218.24 in the same period of 2021[118]. - The net profit attributable to the parent company was ¥169,486,663.20, a decrease of 3.91% from ¥175,169,586.50 in the previous year[119]. - The total comprehensive income for the period was 891.94 million yuan, a decrease of 9.3% compared to the previous period[130]. - The net profit attributable to shareholders was 227.88 million yuan, representing a decrease of 8.8% compared to the same period last year[130]. Cash Flow and Liquidity - The net cash flow from operating activities turned negative at -¥1,157,613,569.68, a significant decline of 1,552.60% compared to ¥79,692,687.05 in the previous year[20]. - Cash and cash equivalents decreased to ¥1,511,098,250, representing 3.87% of total assets, down from 9.85% last year, a decrease of 5.80%[38]. - The company reported a net cash flow from financing activities of 353,607,134.16 yuan in the first half of 2022, a turnaround from -597,580,668.91 yuan in the same period of 2021[125]. - The total cash inflow from financing activities increased to 2,319,745,425.01 yuan in the first half of 2022, up from 1,856,960,954.54 yuan in the previous year, indicating a growth of approximately 24.8%[125]. - The cash inflow from operating activities totaled 13,756,202,690.70 yuan in the first half of 2022, down from 14,177,461,036.49 yuan in the first half of 2021, indicating a decrease of about 3.0%[124]. Assets and Liabilities - Total assets increased by 2.74% to ¥15,346,471,417.04 from ¥14,937,549,976.72 at the end of the previous year[20]. - Accounts receivable increased to ¥8,221,038,900, accounting for 53.57% of total assets, up from 52.13% last year, an increase of 1.44%[38]. - Inventory rose to ¥2,658,145,320, making up 17.32% of total assets, compared to 14.63% last year, an increase of 2.69%[38]. - Short-term borrowings increased to ¥4,234,737,540, representing 27.59% of total assets, up from 24.88% last year, an increase of 2.71%[39]. - Current liabilities totaled ¥9,335,134,102.02 as of June 30, 2022, compared to ¥9,021,803,540.14 at the start of the year, marking an increase of about 3.49%[111]. Operational Highlights - The pharmaceutical wholesale segment generated ¥11.68 billion, accounting for 91.94% of total revenue, but saw a decline of 3.14% compared to the previous year[34]. - The retail pharmacy segment experienced significant growth, with revenue increasing by 113.75% to ¥875.45 million, representing 6.89% of total revenue[34]. - The company successfully secured distribution qualifications for 67 out of 78 products in the ongoing national bulk procurement program, enhancing its competitive edge[29]. - The company has expanded its e-commerce business model in the health sector, achieving growth despite adverse macroeconomic conditions[28]. - The company is actively developing new medical service businesses, with rehabilitation hospitals in Chengdu, Bengbu, and Shenzhen already completed and operational[28]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company plans to enhance its product structure and regional layout to mitigate the impact of price reductions in pharmaceuticals and medical supplies[54]. - The company is focusing on digital transformation, including the development of smart healthcare and online pharmaceutical distribution[63]. - The company plans to expand its market presence by launching new products in the second half of the year[131]. - The company aims to enhance its operational efficiency by implementing new technologies and optimizing existing processes[135]. Risks and Challenges - The company has acknowledged potential risks related to industry competition, management, market conditions, and national policies[3]. - The company reported a decrease in the weighted average return on equity to 4.12% from 4.71% year-on-year[20]. - The company experienced a credit impairment loss of CNY 2,034,967.95, compared to a gain of CNY 385,909.71 in the same period of 2021[122]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 24,029[95]. - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of shares, totaling 41,876,430 shares[95]. - The total number of unrestricted sale condition shares is 250,526,315, representing 85.88% of total shares[92]. - The company has not implemented any share buyback or reduction during the reporting period[93]. Compliance and Governance - The semi-annual financial report was not audited[70]. - The financial report complies with the requirements of the enterprise accounting standards, reflecting the financial position and operating results as of June 30, 2022[153]. - The financial statements are prepared based on the going concern principle and historical cost, except for certain financial instruments[150].